Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)|
Drug: Regorafenib (BAY73-4506)
This "Managed Access Program" covers the different types of programs in the participating countries (including compassionate use program, named patient program, cohorts e.g. ATU in France, etc).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01689376
|Study Director:||Bayer Study Director||Bayer|